Hythiam, Inc.
HYTHIAM ANNOUNCES THIRD QUARTER RESULTS
LOS ANGELES, CALIFORNIA — November 9, 2009 — Hythiam, Inc. (NASDAQ:HYTM) today announced financial results for the third quarter and nine months ended September 30, 2009, which include the consolidated results from Comprehensive Care Corporation (CompCare) through January 20, 2009, the disposition date. As a result of the January 20, 2009 sale, the Company’s results treat CompCare as a Discontinued Operation.
"With the Ford® Motor Company agreement and financing completed, we are focused on concluding deals in the later stages of our pipeline,” said Rick Anderson, Hythiam’s President and COO. “We expect to finish the implementation of the Ford agreement in the Fourth Quarter of 2009, and we expect revenue to begin in the First Quarter of 2010. In addition, we are carefully managing the Company’s existing resources to achieve critical objectives. As part of our sales process, we are gaining traction by offering an integrated solution to customers who recognize the significant cost of substance dependence in their populations and the current fragmented approaches to treatment. We continue to work toward securing final agreements with customers in longer sales cycles, and are also expanding our pipeline,” Anderson concluded.
CONSOLIDATED
The company reported a consolidated net loss of $8.8 million, or $0.16 per share for the third quarter of 2009. This compares with a 2008 third quarter consolidated net loss of $6.3 million, or $0.11 per share, which includes $141,000 of income from discontinued operations, or $0.01 per share. The consolidated net loss for the nine months ended September 30, 2009 amounted to $10.7 million, or $0.19 per share, which includes $10.4 million of income from discontinued operations, or $0.19 per share. This compares with a consolidated loss of $31.1 million for the same period in 2008, or $0.57 per share, which includes a $5.4 million loss from discontinued operations, or $0.10 per share.
CONTINUING OPERATIONS
For the 2009 third quarter, the Company reported revenues of $268,000 from its continuing operations (healthcare services business), compared to revenues from continuing operations of $1.3 million during the comparable period last year. The decrease in healthcare services revenues was primarily attributable to the difficult economy and the Company's decision to streamline operations by reducing operating costs and resources supporting private-pay to focus on managed care opportunities. There were a total of 46 patients treated with the PROMETA® Treatment Program in the third quarter of 2009, compared to 134 patients treated in the third quarter of 2008. During the third quarter of 2009, there were 14 licensee sites contributing to revenues, versus 36 in the same period last year.
Loss from continuing operations for the 2009 third quarter was $8.8 million, or $0.16 per share, versus a loss of $6.4 million, or $0.12 per share, in the third quarter of 2008. Included in the 2009 third quarter loss were consolidated non-cash charges for depreciation, amortization and stock-based compensation expense of $1.4 million, compared to $3.6 million in non-cash charges in the same period in 2008. The loss for the 2009 third quarter also included a $54,000 loss on the partial extinguishment of debt, a $25,000 “other-than-temporary” loss on auction-rate securities and a non-cash charge of $4.8 million from the change in fair value of the Company's warrant liabilities. These charges in the 2009 third quarter were partially offset by a $160,000 gain on the sale of marketable securities. The loss from continuing operations for the 2008 third quarter included a non-cash gain of $3.8 million from the change in fair value of the Company's warrant liabilities.
For the nine months ended September 30, 2009, revenues for continuing operations were $1.3 million, compared to revenues of $5.3 million in the same period in 2008. The decrease in healthcare services revenues was primarily attributable to the difficult economy and the Company's decision to streamline operations by reducing operating costs and resources supporting private-pay to focus on managed care opportunities. Net loss from continuing operations for nine months ended September 30, 2009 was $21.2 million, or $0.38 per share, compared to a net loss of $25.6 million, or $0.47 per share, for the nine months ended September 30, 2008. The net loss for the nine months ended September 30, 2009 included non-cash charges for depreciation, amortization and stock-based compensation expenses of $5.2 million, compared to $9.0 million for similar expenses in the same period in 2008. The net loss for the nine months ended September 30, 2009 also included impairment charges of $1.1 million related to property, equipment and intangible assets, a $330,000 loss on partial extinguishment of debt and $185,000 of impairment charges related to “other-than-temporary” losses on auction rate securities and a non-cash charge of $4.7 million from the change in fair value of the Company's warrant liabilities. The loss from continuing operations for the same period in 2008 included a non-cash gain of $4.7 million from the change in fair value of the Company's warrant liabilities.
As of September 30, 2009, the Company had consolidated cash, cash equivalents, and marketable securities of approximately $7.1 million, excluding auction rate securities of $9.2 million.
In an effort to continue enhancing the Company’s ability to fund ongoing operations, management further reduced yearly operating expenses by an additional $5.7 million during the nine months ended September 30, 2009. The Company will continue to manage expenses, and is focused on signing new agreements with health plans for its Catasys offering.
About the PROMETA® Treatment Program
Hythiam's PROMETA Treatment Program is designed for use by health care providers seeking to treat individuals diagnosed with dependencies to alcohol, cocaine or methamphetamine, as well as combinations of these drugs. The PROMETA Treatment Program includes nutritional supplements, FDA-approved oral and IV medications used off-label and separately administered in a unique dosing algorithm, as well as psychosocial or other recovery-oriented therapy chosen by the patient and his or her treatment provider. As a result, PROMETA represents an innovative approach to managing alcohol, cocaine, or methamphetamine dependence that is designed to address physiological, nutritional, and psychosocial aspects of the disease, and is thereby intended to offer patients an opportunity to achieve sustained recovery. To learn more, please visit www.prometainfo.com.
About Hythiam®
Hythiam, Inc. provides, through its CatasysTM offering, behavioral health management services to health plans, employers and unions through a network of licensed and company managed healthcare providers. The Catasys substance dependence program is built around medical and psychosocial interventions, including the patented PROMETA® Treatment Program for alcoholism and stimulant dependence. The PROMETA Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers and company managed treatment centers. Hythiam does not practice medicine or manufacture, distribute, or sell any medications and has no relationship with any manufacturers or distributors of medications used in the PROMETA Treatment Program. For further information, please visit www.hythiam.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, lack of statistically significant formal research studies, the risk that substance dependence solutions might not be effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the healthcare industry; and additional risks factors as discussed in the reports filed by Hythiam, Inc. with the Securities and Exchange Commission, which are available on its website at http://www.sec.gov.
